Margaret Dugan
CIK 1909734 · Chief Medical Officer · last filed 2026-06-15
Margaret Dugan is a Chief Medical Officer who has filed 18 SEC Form 4 insider transactions across 4 companies since 2022. The most recent filing, for ONC, was dated Jun 15, 2026. Across all open-market trades the lifetime net is −$122.2K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $25.9M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$25.94M
4
18
-$122.2K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ONC | Director | 73,164 | $347.36 | $25.41M | -$65.6K | 3 | 2026-06-15 |
| WHWK | Chief Medical Officer | 19,132 | $4.47 | $85.6K | $0 | 3 | 2026-05-18 |
| SDGR | Chief Medical Officer | 24,574 | $17.77 | $436.7K | -$56.6K | 5 | 2025-10-17 |
| BeOne Medicines Ltd. (BGNE) Delisted | Director | 45,955 | $184.71 | $8.49M | $0 | 4 | 2024-06-07 |
Recent Filings
18 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-15 | ONC | Grant (A) | +18,980 | $0 | EDGAR |
| 2026-05-27 | ONC | Sell (S) | −212 | -$65.6K | EDGAR |
| 2026-05-22 | — | Notice (144) | −212 | -$65.6K | EDGAR |
| 2026-05-18 | WHWK | Grant (A) | +19,132 | $75.0K | EDGAR |
| 2026-04-03 | WHWK | Grant (A) | — | $0 | EDGAR |
| 2025-12-02 | WHWK | Grant (A) | — | $0 | EDGAR |
| 2025-10-17 | SDGR | Sell (S) | −1,395 | -$29.4K | EDGAR |
| 2025-10-16 | SDGR | Notice (144) | −1,395 | -$29.4K | EDGAR |
| 2025-05-22 | ONC | Grant (A) | +10,985 | $0 | EDGAR |
| 2025-03-04 | SDGR | Grant (A) | +12,500 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.